A Contemporary Insight of Metabolomics Approach for Type 1 Diabetes: Potential for Novel Diagnostic Targets
Jiatong Chai,Zeyu Sun,Jiancheng Xu
DOI: https://doi.org/10.2147/DMSO.S357007
2022-05-25
Abstract:Jiatong Chai, Zeyu Sun, Jiancheng Xu Department of Laboratory Medicine, The First Hospital of Jilin University, Changchun, People's Republic of China Correspondence: Jiancheng Xu, Department of Laboratory Medicine, The First Bethune Hospital of Jilin University, 71 Xinmin Street, Changchun, 130021, People's Republic of China, Tel +86-431-8878-2595, Fax +86-431-8878-6169, Email High-throughput omics has been widely applied in metabolic disease, type 1 diabetes (T1D) was one of the most typical diseases. Effective prevention and early diagnosis are very important because of infancy and persistent characteristics of T1D. The occurrence and development of T1D is a chronic and continuous process, in which the production of autoantibodies (ie serum transformation) occupies the central position. Metabolomics can evaluate the metabolic characteristics of serum before seroconversion, the changes with age and T1D complications. And the addition of natural drug metabolomics is more conducive to the systematic and comprehensive diagnosis and treatment of T1D. This paper reviewed the metabolic changes and main pathogenesis from pre-diagnosis to treatment in T1D. The metabolic spectrum of significant abnormal energy and glucose-related metabolic pathway, down-regulation of lipid metabolism and up-regulation of some antioxidant pathways has appeared before seroconversion, indicating that the body has been in the dual state of disease progression and disease resistance before T1D onset. Some metabolites (such as methionine) are closely related to age, and the types of autoantibodies produced are age-specific. Some metabolites may jointly predict DN with eGFR, and metabolomics can further contribute to the pathogenesis based on the correlation between DN and DR. Many natural drug components have been proved to act on abnormal metabolic pathways of T1D and have a positive impact on some metabolic levels, which is very important for further finding therapeutic targets and developing new drugs with small side effects. Metabolomics can provide auxiliary value for the diagnosis of T1D and provide a new direction to reveal the pathogenesis of T1D and find new therapeutic targets. The development of T1D metabolomics shows that high-throughput research methods are expected to be introduced into clinical practice. Keywords: type 1 diabetes, metabolomics, diabetic complications, metabolites, drug targets Type 1 diabetes (T1D) is one of the most common chronic diseases and increasing in prevalence with each passing year, particularly in westernized countries with incidences of 8−17 per 100,000 people in Northern Europe and the US. 1,2 Aside from using insulin to maintain metabolic stability, there are currently no effective therapies for T1D. The traditional diagnosis of T1D, which includes measuring the levels of glucose, glycated molecules and autoantibodies, has been well established. However, these molecules often mark a late stage of the disease when ~90% of the pancreatic insulin-producing β-cells have already been lost. 3 Hence, more attention has been given to early prediction and prevention. The diagnostic methods of T1D are well-established. However, how to monitor the metabolic changes in high-risk groups and intervene in the metabolic pathways involved in the progression to the advanced disease have always been challenging aspects of research. Moreover, acute or multiple organ complications, including diabetic ketoacidosis (DKA), diabetic retinopathy (DR), diabetic nephropathy (DN) and diabetic-induced peripheral neuropathy (DPN), are always found in patients with T1D, and these complications may lead to practical and emotional health concerns for patients and their families. 4 In addition, abnormalities of circulatory metabolism that are caused by T1D will also affect the metabolic state of other organs. Lower levels of choline, betaine and methionine were found in the liver of patients with T1D, which indicates that hyperglycemia might eliminate their protective function against liver injury. 5 More than 19 metabolites, such as choline, c-aminobutyric acid, glutamine, myo-inositol and lactate, have been found in six regions of the brain, such as the hippocampus, cortex and cerebellum. The location of these metabolites can be used to distinguish healthy people from patients with T1D. 6 Impaired amino acid and tricarboxylic acid (TCA) cycle metabolism leads to cardiovascular autonomic neuropathy progression in T1D patients. 7 Moreover, T1D can also cause lipid metabolism disorders of the meibomian gland. 8 Most importantly, T1D often causes abnormal metabolic changes in the kidney, such as changes in the oxidative stress pathway and purine metabolic pathway. 9 Therefore, in view of the great impact of T1D on various organs, it is impor -Abstract Truncated-